116
Congruence Therapeutics has announced the appointment of Charles Grubsztajn as Chief Operating Officer. Grubsztajn brings extensive experience to the role, having previously served as Chief Operating Officer at Congruence Therapeutics.
The company, focused on developing novel therapeutics, operates within the biotechnology sector. Grubsztajn’s leadership is expected to contribute to Congruence Therapeutics’ strategic growth and operational efficiency as it advances its pipeline.
For further information, Charles Grubsztajn can be reached at cgrubsztajn@congruencetx.com. Media inquiries can be directed to Amy Conrad at Juniper Point via email at amy.conrad@juniperpoint.com or by phone at 858-366-3243.
